ERIS Lifesciences IPO: A Quick Take
I just missed this IPO and didn't do any study at all. But my friend Piyush reminded me about this today due to its complete focus on indian market and superior balance sheet. Mr. Naman has done some digging for important points (shared in the comment section) and it looks like a good investment opportunity. As i always feel India is going to be big market in the future for pharma along with Africa and middle east. Eris is debt free having around 300 cr current investments. Capacity utilization is low at 55% so the future growth will provide high…